SCHEMBL7215929

SCHEMBL7215929

O=[N+]([O-])c1ccc2c(c1)C(CN1CCC(c3c[nH]c4ccc(F)cc34)CC1)CC2

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.58
OPRK1 P41145 2/20 0.58
OPRL1 P41146 2/20 0.58
HTR1A P08908 7/20 0.47
SLC6A4 P31645 7/20 0.47
DRD2 P14416 7/20 0.46
HTR2A P28223 5/20 0.46
HTR7 P34969 5/20 0.46
HTR6 P50406 4/20 0.46
HSD11B1 P28845 1/20 0.44
HTR1D P28221 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795043 0.84 OPRM1 (0.60) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL7220179 0.82 SLC6A4 (0.53) HTR1ASLC6A4DRD2HTR2AHTR7
SCHEMBL6796075 0.80 HTR1D (0.60) OPRM1OPRK1OPRL1HTR1ADRD2
Fumaric Acid SCHEMBL7219907 0.79 OPRM1 (0.52) OPRM1OPRK1OPRL1HTR1ASLC6A4
Fumaric Acid SCHEMBL7219910 0.79 OPRM1 (0.52) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL6601282 0.77 OPRM1 (0.53) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL14280674 0.74 OPRL1 (1.00) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL6640192 0.74 HTR1D (0.63) HTR1ASLC6A4HTR1D
SCHEMBL7214486 0.74 OPRM1 (0.56) OPRM1OPRK1OPRL1HTR1ASLC6A4
SCHEMBL7214372 0.72 ADRA1D (0.58) OPRM1OPRK1OPRL1HTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552044-B2 Dopamine receptors H. LUNDBECK A/S (DK) 2003-04-22 US disclosed
EP-0946542-B1 INDANE OR DIHYDROINDOLE DERIVATIVES LUNDBECK & CO AS H (DK) 2002-10-09 EP disclosed
US-6352988-B2 HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION H. LUNDBECK A/S (DK) 2002-03-05 US disclosed
US-20010021777-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-13 US disclosed
US-6262087-B1 HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. H. LUNDBECK A/S (DK) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021777-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 OPRM1 34/4885OPRK1 23/4885OPRL1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.